See more : DiGiSPICE Technologies Limited (DIGISPICE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of CARsgen Therapeutics Holdings Limited (2171.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CARsgen Therapeutics Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- T Stamp Inc. (IDAI) Income Statement Analysis – Financial Results
- Unieuro S.p.A. (0ROF.L) Income Statement Analysis – Financial Results
- VITA 34 AG (VTIAF) Income Statement Analysis – Financial Results
- Accuray Incorporated (ARAY) Income Statement Analysis – Financial Results
- Walrus Pump Co., Ltd. (6982.TWO) Income Statement Analysis – Financial Results
CARsgen Therapeutics Holdings Limited (2171.HK)
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 25.81M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 25.81M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 661.66M | 680.30M | 501.72M | 281.75M | 210.20M |
| General & Administrative | 127.84M | 46.82M | 65.82M | 54.80M | 8.75M |
| Selling & Marketing | 5.47M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.31M | 46.82M | 65.82M | 54.80M | 8.75M |
| Other Expenses | -27.32M | 75.16M | 44.27M | 12.12M | 11.41M |
| Operating Expenses | 767.65M | 802.28M | 611.80M | 348.67M | 230.36M |
| Cost & Expenses | 767.65M | 802.28M | 611.80M | 348.67M | 230.36M |
| Interest Income | 68.13K | 27.57M | 9.61M | 763.00K | 2.91M |
| Interest Expense | 0.00 | 15.52M | 10.87M | 13.48M | 887.00K |
| Depreciation & Amortization | 67.41M | 56.92M | 52.45M | 32.27M | 14.28M |
| EBITDA | -717.64M | -793.90M | -517.89M | -286.17M | -206.40M |
| EBITDA Ratio | 0.00% | 0.00% | -2,006.32% | 0.00% | 0.00% |
| Operating Income | -767.65M | -881.30M | -585.99M | -327.05M | -227.40M |
| Operating Income Ratio | 0.00% | 0.00% | -2,270.13% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.26M | -9.66M | -4.16B | -737.00M | -37.73M |
| Income Before Tax | -747.39M | -890.95M | -4.74B | -1.06B | -265.13M |
| Income Before Tax Ratio | 0.00% | 0.00% | -18,350.36% | 0.00% | 0.00% |
| Income Tax Expense | 407.00K | 1.30M | 7.65M | 737.77M | 39.16M |
| Net Income | -747.79M | -892.25M | -4.74B | -1.80B | -304.30M |
| Net Income Ratio | 0.00% | 0.00% | -18,379.98% | 0.00% | 0.00% |
| EPS | -1.34 | -1.62 | -8.63 | -8.55 | -5.36M |
| EPS Diluted | -1.34 | -1.62 | -8.63 | -8.55 | -5.36M |
| Weighted Avg Shares Out | 556.13M | 551.63M | 549.89M | 210.69M | 56.73 |
| Weighted Avg Shares Out (Dil) | 556.13M | 551.63M | 549.89M | 210.69M | 56.73 |
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit
Source: https://incomestatements.info
Category: Stock Reports